Cencora poised for growth as AI boosts prescription volumes and operational efficiency.

Cencora (COR) is expected to benefit from AI-driven increases in prescription volumes, supported by regulatory pilots expanding automated prescribing. The company's operational leverage and AI-enabled efficiency improvements have led to a 17% year-over-year rise in adjusted operating income, outpacing its 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x, about 25% below the sector median, Cencora could see a 12.5% re-rating with a target share price of $365–$366. Risks include potential reimbursement policy changes and regulatory delays, but Cencora's asset-heavy distribution model positions it better than vertically integrated telehealth providers.

Cencora (COR) shares are trading at USD 333.17 on Pluang, showing a modest gain of 0.93% in the last day. The stock's market cap stands at $62.99 billion as of Oct 14, 2026 20:51 WIB, reflecting steady investor interest amid ongoing sector developments.